| Amal Therapeutics–SEVERAL: investment, 201709 financing round Series B first closing €8m co-led by BIVF + BioMedPartners + Helsinn |
2017-09-05 |
| Amal Therapeutics–VI Partners: investment, 201709 financing round Series B first closing totalling €8m incl co-investor VI Partners |
2017-09-05 |
| Immunic–SEVERAL: investment, 201709 financing round Series A extension €10m led by LSP bringing total Series A to €31.7m |
2017-09-05 |
| Metabolomic Discoveries–Metabolon: investment, 201709 acquisition €na of Metabolomic Discoveries GmbH by Metabolon Inc |
2017-09-05 |
| Pharnext–MC Services: public relations, 201709 service existent investor relations Europe by MC Services |
2017-09-05 |
| Boehringer–Allcyte: drug discovery, 201709– collab using Pharmacoscopy ex vivo drug response profiling platform for BI oncology candidates |
2017-09-04 |
| Amcure–Germany (govt): grant, 201708 BMBF research grant €1.75m to advance clinical lead candidate AMC303 |
2017-08-31 |
| Angiex–Merck (DE): drug development services, 201708– supply BioReliance End-to-End Solutions for developm of ADC therapy of Angiex Inc |
2017-08-29 |
| Apeiron–EU (govt): credit, 201708– EIB EFSI loan €25m to support developm of cancer drugs |
2017-08-28 |
| Kite Pharma–Gilead: investment, 201708–201710 acquisition $11.9b cash tender offer $180/share |
2017-08-28 |
| Natrix Separations–Merck (DE): investment, 201708– acquisition €na of Natrix Separations by Merck ANNOUNCED |
2017-08-28 |
| Aurealis Pharma–SEVERAL: investment, 201708 financing round Series A CHF5.6m from private investors + Finnvera + Tekes |
2017-08-25 |
| Novartis–Xoma: IL-1 beta antibodies, 201708– license $26m upfront + $5m investment + milestones + royalties ww rights to gevokizumab + IL-beta Ab IP |
2017-08-25 |
| Labfolder–Germany (govt): business development, 201708– supply service support in US with German Accelerator Life Sciences programme |
2017-08-24 |
| Macrophage Pharma–Merck (DE): investment, 201708 financing round Series A extension with new investor Merk Ventures |
2017-08-23 |
| Batavia–UGA Biopharma: cell line development, –201708 collab devleopm of 2 enzmye expressing monoclonal cell lines for biopharma production |
2017-08-22 |
| CRISPR Therapeutics–Partners HealthCare: cell therapy, 201708– collab research + license option 2y w MGHCC develop cancer T cell therapies w CRISPR |
2017-08-22 |
| Lilly–Topas Therapeutics: immuno modulatory compounds, 201708– collab €na multi-y research + option agreem |
2017-08-22 |
| Micro-Sphere–Ramarketing: public relations, 201708– service by Ramarketing |
2017-08-22 |
| AstraZeneca–Ethris: mRNA-based therapeutics, 201708– collab research 5y w €25m upfront + funding + milestones using SNIM®RNA technology |
2017-08-21 |
| Ethris–MacDougall Biomedical Communications: public relations, 201708 service existent by MacDougall |
2017-08-21 |
| Rodos BioTarget–SEVERAL: investment, 201708 capital increase €800k via crowdfunding platform Aescuvest |
2017-08-18 |
| Biotecon–Bruker: mass spectrometer, 201708– distribution OEM of MALDI Biotyper platforms for food analysis in DACH region + Eastern Europe |
2017-08-16 |
| Monsanto–ToolGen: CRISPR technology, 201708– license ww €na for use of ToolGen’s CRISPR technology platform in agricultural products |
2017-08-16 |
| Roche–Mimetas: organ-on-a-chip technology, –201708 collab developm gut model on-a-chip using OrganoPlate platform |
2017-08-16 |
| Purdue Pharma–CellAct: cancer drug, 201708– acquisition ww developm + commerc rights to CAP7.1 by Mundipharma from CellAct |
2017-08-14 |
| Roivant–SEVERAL: investment, 201708 financing round $1.1b led by SoftBank Vision Fund + incl Dexxon investor group |
2017-08-09 |
| Roivant–SoftBank: investment, 201708 financing round totalling $1.1b incl new + lead investor SoftBank Vision Fund |
2017-08-09 |
| Diagnosticum (HU)–Bruker: food analysis, 201708 collab to form Hungarian Wine Consortium using NMR FoodScreener for wine analysis |
2017-08-08 |
| IFM Therapeutics–BMS: investment, 201708– acquisition two cancer assets for $300m upfront + up to $2.02b milestones |
2017-08-03 |
| Bruker–OTHER: immunoassay technology, 201708 acquisition €na of portable chip-based ELISA platform by Bruker |
2017-08-02 |
| Homology Medicines–HBM: investment, 201708 financing round Series B totalling $83.5m incl new + co-investor HBM Healthcare Investments |
2017-08-01 |
| Homology Medicines–Novartis: investment, 201708 financing round Series B totalling $83.5m incl new + co-investor Novartis |
2017-08-01 |
| Homology Medicines–SEVERAL: investment, 201708 financing round Series B $83.5m led by Deerfield Management |
2017-08-01 |
| Lyocontract–Lyomark Pharma: investment, 201708 acquisition of majority share in Lyocontract GmbH by Lyomark Pharma GmbH |
2017-08-01 |
| Aptuit–Evotec: investment, 201707–201708 acquisition $300m in cash of Aptuit from Welsh, Carson, Anderson & Stowe |
2017-07-30 |
| Evoxx Technologies–Advanced Enzyme Technologies: investment, 201707– acquisition 100% by Advanced Enzymes ANNOUNCED |
2017-07-28 |
| Protembis–Germany (govt): grant, 201507 BMBF grant 7-digit € for Protembis in collab with RWTH Aachen |
2017-07-28 |
| Evosciences–Danaher: mass spectrometer, 201707– distribution of Sciex MS systems with flexible finacing packages via Evosciences in Europe |
2017-07-27 |
| Genkyotex–Alize RP: public relations, 201707 service existent media relations by Alize RP |
2017-07-27 |
| Genkyotex–LifeSci: public relations, 201707 service existent in US by LifeSci Advisors |
2017-07-27 |
| Genkyotex–NewCap: public relations, 201707 service existent IR by NewCap |
2017-07-27 |
| JnJ–Proteros: drug discovery services, 201707– collab €na lead discovery small molecule cancer drugs using NEAT for Jannsen Biotech |
2017-07-27 |
| stimOS–Baden-Württemberg (govt): investment, 201707 seed financing round totalling €720k from HTGF + MBG Baden-Württemberg |
2017-07-27 |
| stimOS–High-Tech Gründerfonds: investment, 201707 seed financing round totalling €720k from HTGF + MBG Baden-Württemberg |
2017-07-27 |
| stimOS–SEVERAL: investment, 201707 seed financing round €720k from HTGF + MBG Baden-Württemberg |
2017-07-27 |
| Storm Therapeutics–Evotec: drug discovery services, 201707– supply service expansion €na HTS + structural biology plus chemistry + new targets |
2017-07-27 |
| Jazz Pharmaceuticals–XL-protein: PASylation technology, 201707– license $2m upfront + funding + milestones + royalties to develop asparaginase drugs |
2017-07-26 |
| Micro-Macinazione–Lonza: investment, 201707 acquisition €na of Micro-Macinazione from Cross Equity Fund |
2017-07-26 |
| DiaSorin–Siemens: ELISA immunoassays, 201707– acquisition up to €47.5m of Siemens ELISA Dx portfolio/assets without employees + mftg capacity |
2017-07-25 |
| Protembis–Germany (govt): business development, 201707– supply service support in US with German Accelerator Life Sciences programme |
2017-07-25 |
| Bayer–Evotec: drug discovery services, 201707–201812 collab extension endometriosis alliance after reaching milestone of start of phase 1 |
2017-07-24 |
| Boehringer–Philogen: drug discovery services, 201707– collab €na discovery + optimisation of small molecule drugs using ESAC technology |
2017-07-20 |
| Spindiag–OTHER: investment, 201707 seed financing round €1.6m from three private investors |
2017-07-20 |
| Humabs BioMed–MC Services: public relations, 201707 service existent by MC Services AG |
2017-07-18 |
| Shire–Novimmune: therapeutic antibodies, 201707– license ww excl €na to bispecific antibody for hemophilia A |
2017-07-18 |
| TomTec Imaging–Philips: investment, 201707– acquisition €na of TomTec Imaging Systems GmbH by Philips ANNOUNCED |
2017-07-18 |
| BASF–Kaiima: plant biotechnology, 201707– collab research multi-year using EP technology to discover herbicide resistent traits |
2017-07-17 |
| Maruho–4SC: Kv1.3 inhibitors, 201707–202009 license ww excl for up to total €208m upfront + milestones plus royalties TERMINATED 9/20 |
2017-07-15 |
| Diagenode–PreOmics: proteomic sample preparation, –201707 collab developm combi of Bioruptor + iST Kit to clean peptides for MS |
2017-07-14 |
| NofaGroup–Cotecna: investment, 201707 acquisition of NofaGroup by Cotecna Inspection SA |
2017-07-13 |
| ABF–Genedata: bioinformatics, 201707– supply expansion use of Genedata Selector by AB Enzymes for decision support |
2017-07-11 |
| Blueprint Genetics–Creathor Ventures: investment, 201707 financing round totalling up to €14m incl new + co-lead investor Creathor Venture |
2017-07-11 |
| Blueprint Genetics–Inventure: investment, 201707 financing round totalling up to €14m incl existing + co-investor Inventure |
2017-07-11 |
| Blueprint Genetics–MedTech Innovation Partners: investment, 201707 financing round totalling up to €14m incl new + co-lead investor MTIP |
2017-07-11 |
| Blueprint Genetics–Pontos Group: investment, 201707 financing round totalling up to €14m incl existing + co-investor Pontos Group |
2017-07-11 |
| Blueprint Genetics–SEVERAL: investment, 201707 financing round up to €14m led by Creathor Venture + MTIP + incl Inventure + Pontos Group |
2017-07-11 |
| Nestlé–Enterome: diagnostics, 201707– collab establishm of 50/50 jv MDP to develop microbiome-based diagnostics except for immuno-oncology |
2017-07-11 |
| CRISPR Therapeutics–Neon Therapeutics: T cell therapy, 201707– collab combi of proprietary technologies to develop T cell therapies |
2017-07-10 |
| Endress+Hauser–GUS Group: investment, 201707 acquisition of AJ Blomesystem GmbH by GUS Group |
2017-07-01 |
| Evotec–Hamburg (govt): grant, 201707– 201906 RnD grant from IFB Hamburg to develop AB-based cancer therapies with UKE |
2017-07-01 |
| Global Bioenergies–SEVERAL: investment, 201706 capital increase €10.24m via private placement of 640k new shares at €16/share |
2017-06-30 |
| mySugr–Roche: investment, 201706 acquisition of remaining shares by Roche |
2017-06-30 |
| Evotec–Censo Biotechnologies: stem cell technology, 201706–201905 strategic collab €na with Censo supplying iPS cell lines to Evotec |
2017-06-28 |
| Indi Molecular–Merck (DE): investment, 201706 financing round Series A totalling $11.5m led by Merck Ventures + Legend Capital |
2017-06-28 |
| Indi Molecular–SEVERAL: investment, 201706 financing round Series A $11.5m led by Merck Ventures + Legend Capital |
2017-06-28 |
| BioGeneration Ventures–EU (govt): investment, 201706 investment by EIF + other new investors bringing total capital of BGV III to €66m |
2017-06-27 |
| BioGeneration Ventures–SEVERAL: investment, 201706 investm by EIF + other new investors bringing total capital of BGV III to €66m with max target €75m |
2017-06-27 |
| Catalym–BioGeneration Ventures: investment, 201706 CatalYm GmbH is existent investment of BGV III fund |
2017-06-27 |
| Sensovation–Miltenyi Biotec: investment, 201706 acquisition by Milteny from HeidelbergCapital + KfW/tbg |
2017-06-27 |
| Takeda–JSR Corp: cell line development, 201706– commercial license to use Selexis’ SUREtechnology for developm of fusion proteins |
2017-06-27 |
| Ottobock–EQT: investment, 201706 EQT VII fund to acquire 20% stake from Otto Bock HealthCare GmbH valuing Ottobock at €3.15b |
2017-06-24 |
| DiaSorin–Qiagen: in vitro diagnostics, 201706– collab to adopt select Qiagen assays for use on Liaison platform |
2017-06-22 |
| Repare Therapeutics–SEVERAL: investment, 201706 financing round Series A $68m co-led by Versant Ventures + MPM Capital |
2017-06-22 |
| AlsaChim–Shimadzu: investment, 201706 acquisition €na of 100% of AlsaChim by Shimadzu Europe |
2017-06-21 |
| FB Health–Invent Farma/Neuraxpharm: investment, 201706 acquisition €na of FB Health by Invent Farma/Neuraxpharm (formed 8/16 by Apax Partners) |
2017-06-21 |
| Debiopharm–Almac: kinase inhibitor, 201706– license ww excl to Wee-1 kinase inhibitor programme of Almac Discovery |
2017-06-20 |
| Facio Therapies–Evotec: investment, 201706c financing round totalling €4.8m incl strategic investment by Evotec |
2017-06-20 |
| Facio Therapies–SEVERAL: investment, 201706c financing round €4.8m incl Evotec + members of intl FSHD community |
2017-06-20 |
| Idorsia–JnJ: investment, 201706 acquisition of 9.9% share in Idorsia by Cilag Holding AG via conversion of CFH135.4m convertable loan |
2017-06-20 |
| Euroimmun–PerkinElmer: investment, 201706–201712 acquisition $1.3b in cash |
2017-06-19 |
| Hopp Group–CRS Clinical Research Services: investment, 201706 management buy-out of CRS from LTS via holding Apleonex AG |
2017-06-19 |
| Takeda–Wilex: antibody-drug conjugates, 201706– collab developm of ADCs using ATACs for up to 3 targets Heidelberg Pharma + Millennium |
2017-06-19 |
| TxCell–Miltenyi Biotec: lentiviral vector, 201706– supply of lentiviral vector for TxCell’s CAR-Tregs targeting transplant rejection by Lentigen |
2017-06-19 |
| Broughton Laboratories–Thermo Fisher: LC system, 201706 supply two Vanquish Flex UPLC systems coupled to TSQ Endura TQ-MS detectors |
2017-06-16 |
| Broughton Laboratories–Thermo Fisher: mass spectrometer, 201706 supply two Vanquish Flex UPLC systems coupled to TSQ Endura TQ-MS detectors |
2017-06-16 |
| GreenBone–Helsinn: investment, 201706 2nd financing round incl €2m from lead investor Helsinn Investment Fund |
2017-06-16 |
| GreenBone–SEVERAL: investment, 201706 2nd financing round incl lead investor Helsinn Investment Fund |
2017-06-16 |
| Idorsia–OTHER: investment, 201706 listing at SIX Swiss Exchange as part of acquisition of Actelion by JnJ and spin-off of Idorsia |
2017-06-16 |
| Medicxi Ventures–Alphabet: investment, 201706 closing totalling $300m of MG1 fund incl cornerstone investors EIF + Novartis + Verily |
2017-06-15 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 21 22 23 ... 29 30 31 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
